LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M-8.7% YoY

Gross Profit

$45M76.1% margin

Operating Income

$12M20.8% margin

Net Income

$404,0000.7% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+18.1%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$15M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$234M

Stockholders' Equity

$816M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$65M	-8.7%
Gross Profit	$45M	$53M	-15.6%
Operating Income	$12M	$16M	-21.4%
Net Income	$404,000	$14M	-97.1%

Revenue Segments

Material Sales, Captisol

$36M27%

Material Sales, Captisol, COVID

$32M24%

Royalty

$20M15%

Contract Revenue

$10M8%

Kyprolis

$9M7%

Contract Revenue, Service

$5M4%

Teriparatide Injection

$4M3%

Milestone

$4M3%

Material Sales, Captisol, Core

$4M3%

Evomela

$3M2%

Rylaze

$2M2%

Royalty, Other

$1M1%

License Fees, Milestones, and Product, Other, Product, Other

$1M1%

License Fees

$460,0000%